Clinical trial
A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)
NCT04154943 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)
- Lead sponsor
- Regeneron Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 10, 2020
- Completion date
- November 19, 2025
- Enrollment
- 79 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.